IGEN gets $505 million damages and exit from Roche deal
This article was originally published in Clinica
Executive Summary
Tiny US company IGEN international has won a highly significant victory in the courts against Swiss giant Roche Diagnostics. Roche has been ordered to pay IGEN $505 million in damages in the companies' long-running dispute over the licensing of IGEN's Origen electrochemiluminescence (ECL) technology to Roche. It also allows IGEN to end its licence agreement with Roche.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.